Image (Lenalidomide Chemical Structure)
Chemical structure of lenalidomide, showing its molecular framework with amine, carbonyl, and cyclic components.*
Lenalidomide Capsule
Product Images NDC 76282-701
13 FDA label images from Exelan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 76282-701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Lenalidomide Figure 01)
A survival probability graph showing progression-free survival (in months) for three treatment groups: Rd Continuous, Rd18, and MPT. The graph includes survival curves for each group, a risk table below indicating the number of subjects at risk at different time points, and hazard ratios with confidence intervals and a logrank p-value for comparisons between treatments.*
2 (Lenalidomide Figure 02)
A Kaplan-Meier survival curve chart depicting overall survival probability over months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart shows survival percentages on the vertical axis and time in months on the horizontal axis, with three distinct colored lines representing each treatment group's survival trends and hazard ratios with confidence intervals noted.*
3 (Lenalidomide Figure 03)
A Kaplan-Meier progression-free survival curve comparing lenalidomide versus placebo over time in months. The graph shows a higher progression-free survival probability for lenalidomide compared to placebo. The accompanying table below the graph displays the number of subjects at risk at various time points, along with event counts and percentages for each group.*
4 (Lenalidomide Figure 04)
A Kaplan-Meier survival curve chart showing progression-free survival probability over months for Lenalidomide versus Placebo. The blue solid line represents Lenalidomide, and the red dashed line represents Placebo. The graph includes hazard ratio data and median survival times with confidence intervals, as well as the number of subjects at risk over time for each group.*
5 (Lenalidomide Figure 05)
A Kaplan-Meier survival curve comparing time to progression (months) between two groups: Lenalidomide/Dex and Placebo/Dex. The vertical axis shows the proportion of subjects, with Lenalidomide/Dex group showing longer progression-free time. The chart includes hazard ratio (HR = 0.285) with 95% confidence interval and a log-rank p-value less than 0.001.*
6 (Lenalidomide Figure 06)
A Kaplan-Meier survival curve comparing time to progression (months) for subjects treated with Lenalidomide/Dex versus Placebo/Dex. The vertical axis shows the proportion of subjects, and the horizontal axis shows time to progression in months. The graph includes a hazard ratio (HR) with 95% confidence interval and a log-rank p-value indicating statistical analysis results.*
Image-1 (Lenalidomide Figure 07)
A Kaplan-Meier survival curve comparing progression-free survival over 48 months for two groups: Rituximab plus Lenalidomide versus Rituximab plus Placebo. The y-axis shows survival probability, and the x-axis shows time in months. The graph includes the number of subjects at risk at various time points and a hazard ratio with confidence interval and significance level.*
Container-5mg-genvion (Lenalidomide 5mg)
Label for lenalidomide capsules 5 mg, manufactured by Cipla Ltd and labeled by Exelan Pharmaceuticals Inc. The package contains 28 capsules. Warning for potential human birth defects is prominently displayed. Storage instructions specify 20°C to 25°C with allowed excursions. The label includes barcode and directions to dispense a Medication Guide.*
Container-10mg-genvion (Lenalidomide 10mg)
Lenalidomide Capsules 10 mg label for oral use by Exelan Pharmaceuticals Inc. The label includes a warning for potential human birth defects, pharmacist instructions to dispense a medication guide, and states the package contains 28 capsules. Storage instructions and manufacturer details (Cipla Ltd. and Genvion Corporation, Canada) are also provided alongside a barcode and NDC 76282-698-48.*
Container-15mg-genvion (Lenalidomide 15mg)
Label for Lenalidomide Capsules 15 mg by Exelan Pharmaceuticals Inc. The label includes a warning about potential human birth defects and instructs pharmacists to dispense the medication guide. It states each capsule contains 15 mg of lenalidomide, provides storage instructions, and shows the manufacturer as Cipla Ltd. The label includes a barcode and indicates a package count of 21 capsules.*
Container-20mg-genvion (Lenalidomide 20mg)
Label for lenalidomide capsules, 20 mg strength, with NDC 76282-700-47. The label includes a warning about potential human birth defects and instructions for pharmacists to dispense the medication guide. It indicates a package size of 21 capsules, is marked Rx Only, and is manufactured by Cipla Ltd. for Exelan Pharmaceuticals Inc., Boca Raton, FL. Storage instructions and barcode are also present.*
Container-25mg-genvion (Lenalidomide 25mg)
Label for lenalidomide capsules 25 mg by Exelan Pharmaceuticals Inc. The label includes a warning about the potential for human birth defects and directs pharmacists to provide a medication guide. It lists 21 capsules per container and storage instructions. The label also shows the manufacturer Cipla Ltd. and includes a barcode.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
